ALK-Abelló's ACARIZAX trial in China hits primary efficacy targets, strengthening the company's expansion strategy in partnership with GenSci to address a massive,…
Actinium Pharmaceuticals will showcase Phase 1 clinical results for ATNM-400 at EANM 2026, targeting advancements in prostate and lung cancer treatments beyond…
The appointment of Dr. Beaston, a veteran FDA official, bolsters the regulatory and clinical strategy for Sernova and Seraxis as they integrate…
Caris Life Sciences partners with Jordan Spieth to promote its AI-driven cancer screening technology in a new national commercial campaign.
IDEAYA Biosciences shares gain momentum as new clinical trial data confirms the efficacy of its darovasertib combination therapy in treating metastatic uveal…
Eli Lilly eyes label expansion for Omvoh after pediatric ulcerative colitis trial data shows 80% induction response rate, strengthening the drug's clinical…
Eli Lilly prepares to present key clinical trial updates for its investigational oncology candidates, including sofetabart mipitecan and olomorasib, at the upcoming…
Pleasanton-based n6 Tec secures ISO 13485:2016 certification, marking a key operational milestone for its iconPCR genetic research instrumentation and quality management processes.
Biosergen AB will be delisted from Nasdaq First North on October 22, 2026, as the company completes its merger with Flerie AB,…
Actinium Pharmaceuticals shares gain momentum as new clinical data from EANM 2026 confirms ATNM-400's broad antitumor activity across diverse cancer models, including…
Scinai Immunotherapeutics secures $4 million in new funding via private placement, impacting shareholder equity as the firm scales its CDMO and therapeutic…
Nabsys 2.0, LLC expands its genomic diagnostic capabilities with the release of RepX, a cost-effective pipeline targeting 23 distinct disease-associated repeat expansion…